Weekly Analysts’ Ratings Changes for Fresenius Medical Care AG & Co. KGaA (FMS)

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) recently received a number of ratings updates from brokerages and research firms:

• 7/28/2026 – Fresenius Medical Care AG & Co. KGaA was downgraded by BNP Paribas Exane from “neutral” to “underperform”. They now have a $19.90 price target on the stock.
• 7/28/2026 – Fresenius Medical Care AG & Co. KGaA was upgraded by BNP Paribas Exane to “strong sell”.
• 7/17/2026 – Fresenius Medical Care AG & Co. KGaA had its “neutral” rating reaffirmed by Citigroup Inc..
• 7/16/2026 – Fresenius Medical Care AG & Co. KGaA is now covered by Sanford C. Bernstein. They set a “market perform” rating on the stock.
• 7/6/2026 – Fresenius Medical Care AG & Co. KGaA was upgraded by Zacks Research from “strong sell” to “hold”.

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.